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Reduction in the duration of a study and in the number of patients required can be obtained when we
adopt a sequential design. In this paper we re-analyse a trial completed by the British Medical Research
Council on the effects of chemotherapy to prevent the recurrence of surgically removed superﬁcial
bladder cancer as if it had been monitored sequentially. The aim is to illustrate the use and beneﬁts of
sequential designs (stopping rules) and to highlight how to handle some potential problems when the
assumptions of the statistical model are not satisﬁed. These problems are not exclusive to the sequential
design, but are also present when a conventional design is used.
 2009 Published by Elsevier Ltd on behalf of Surgical Associates Ltd.1. Introduction
The purpose of a sequential design (stopping rules) is to stop
recruitment as soon as a conclusive result is found, either because
there is evidence that there is no treatment difference or because
a signiﬁcant difference between the treatments emerges, reducing
patient exposure to the inferior treatment. If stopping occurs after
patient recruitment has ceased and collection of follow-up data on
existing patients continues, early conclusion and publicationwould
more quickly affect policy. Sequential methods have already been
applied to a wide range of trials with a variety of outcomes.15,8,1
The validity and beneﬁt of sequential over conventional designs
have been demonstrated by re-analysing a good number of
completed studies in different medical ﬁelds.12 Rosner and Tsiatis
took70 rct’s that hadbeen analysedwith conventional ﬁxed-sampled in the First International
niversity, Alabama, US; July
x: þ44 02078485517.
onaldson).
Elsevier Ltd on behalf of Surgical Amethods and re-analysed them using sequential methods. Their
results were generally consistent with those of the original papers
and inmost of themwith a considerable saving in the sample size at
the time of the analysis. However, applications to trials with long-
term follow-up survival data remains a special challenge. Because
sequential design (planned interim analyses) must be carefully
tailored for each individual trial, we have conducted in-depth
studies of a numberof interesting trials. Twoof our case studies have
already been published in themedical literature.4,5 In this paper we
re-analyse a clinical trial in surgery to do an informative comparison
between sequential (interim analyses) and conventional (ﬁxed-
sample) designs. We illustrate how to implement correctly the
sequentialmethodology in a survival studywhere a potential pitfall,
peculiar to long-term survival studies, was identiﬁed: the assump-
tion of proportionality of hazards was not holding early on.
The form of sequential design we used is that described by
Whitehead16,18 and implemented in the computer package
PEST3.2,18 The trial concerned was conducted by the Urological
Working Party of the MRC and the results have been reported by
Tolley et al.14 A sequential design similar to that described here has
been prospectively adopted for a long-term survival trial in meta-
static renal carcinoma.7 In the next section, details will be given ofssociates Ltd.
c It crosses the upper boundary at the 5th interim look. Follow-up of recruited
patients would have conﬁrmed the beneﬁt of MMCx1 in a sixth inspection and
thereafter.
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described in Section 3. The simulated sequential trial is presented
in Section 4.
2. The MRC superﬁcial bladder cancer trial of intravesical
mitomycin-c
Unlike most cancers, superﬁcial bladder cancer is rarely a fatal
disease, with more than 95% of patients surviving for longer than 5
years.6 Nevertheless, upto 70% of patients are likely to have
a recurrence of disease at some stage after initial surgical resection
(transurethral resection-TUR) of the tumour.11 Once the disease
recurs it does have a tendency to keep recurring, despite surgical
treatment. Between March 1984 and September 1987 the superﬁ-
cial bladder cancer subgroup of the MRC Urological Working Party
recruited patients to a multi-centre national trial to assess whether
instilling mitomycin-c into the bladder would help to reduce both
the proportion of patients experiencing a recurrence and also the
number of recurrences for each patient. The full details of the trial
are given elsewhere.14 After complete surgical resection of all
visible tumour, 457 eligible patients were randomised in approxi-
mately equal proportions to one of the three groups: no instillation
of mitomycin-c (control); a single instillation of mitomycin-c to be
given immediately (MMCx1); a single instillation of mitomycin-c
again to be given immediately, followed by a further 4, to be given
at three monthly intervals over a period of a year (MMCx5). All
patients had follow-up cystoscopies every three months for the
ﬁrst year, twice in the second year and annually thereafter.
At the time of designing the trial a two-year recurrence-free
survival rate of 0.46 was anticipated for the control. According to
the protocol, the target improvement of 0.20would take this to 0.66
for the MMCx1 group. If a proportional hazards model is assumed,
then the target improvement above can be expressed as a hazard
ratio (MMCx1: Control) of 0.535. Our design is set to test the two-
sided alternative that the effect of MMCx1 is different from that of
the control treatment, either superior or inferior.
If a power of 90% is speciﬁed for obtaining signiﬁcance at the 5%
level (2-sided alternative) when the hazard ratio is 0.535, then
about 108 recurrences are required. According to the protocol, it
was hoped that the 400 patients planned should be recruited in just
over 2 years, and this number would be likely to lead to about 108
recurrences during the study period.
The third treatment arm, MMCx5, will not be considered further
in this paper.
An analysis of the data was published in 1988 after a median
follow-up of approximately one year. The analysis of the time to
ﬁrst recurrence, the main outcome, gave a p-value of 0.50 for the
comparison of MMCx1 with control (hazard ratio¼ 0.88; 95%
CI¼ 0.62–1.27). Thus at this stage, the conclusion was that there
was no reliable evidence of a difference between MMCx1 and
control in terms of the times to ﬁrst recurrence. Analyses of the
secondary endpoint, recurrence rate per annum and tumour rate
per annum, did show signiﬁcant differences, between MMCx1 and
control. A further analysis of the datawas performed in March 1992
after a median follow-up of approximately 3 years. With this extra
follow-up, there was good evidence of different times to ﬁrst
recurrence, between the MMCx1 and control (p-value¼ 0.009;
hazard ratio¼ 0.66; 95% CI¼ 0.48–0.90).
3. The sequential design
3.1. Rationale for the choice of stopping rule
With the mentioned power requirement for a two-sided alter-
native, the sequential methods offer two options: asymmetric (asingle triangle) or symmetric (a double triangle or a restricted
procedure) power requirements [reference]. In both cases,
symmetric or asymmetric, if the 2-year survival rate is 0.20 better
for the MMCx1, the power of detecting superiority of MMCx1 is
90%. However, if the 2-year survival is 0.20 worse for MMCx1 (than
for control), the power of detecting that the control is inferior is still
90% for the double triangular test but is relaxed for the single
triangular test (to 29% in this case). We chose asymmetric power
requirement because it was important to demonstrate inferiority of
MMCx1 if it existed, in order to discourage use of a widely available
and popular therapy, given the convenience, non-toxicity and
potential beneﬁt of mitomycin-c. Among the symmetric designs we
considered the double triangular and the restricted procedure
(O’Brien & Flemming rule). We chose the double triangle over the
restricted procedure because of the desire to stop early if it became
evident that no signiﬁcant treatment difference was to be found,
avoiding a long, and eventually futile trial. We wish to avoid futile
trials especially if there is a risk of toxicity with one of the treat-
ments. In our study, given the safety of MMCx1 the concern was
with the cost. The other reason to choose the double triangle was to
avoid the stringent boundaries of the restricted procedure (O’Brien
& Flemming rule) to be able to react to an early and overwhelming
treatment effect. The statistic Z plotted on the y-axis is a cumulative
measure of the observed advantage of MMCx1 over control: the
log-rank statistic. The statistic V plotted on the x-axis is a measure
of the information available, a function of the sample size,
approximately equal to a quarter of the number of recurrences.3
In the ﬁnal analysis of a survival study, Cox’s proportional
hazards regression model is often applied in order to compare
treatments, adjusting for prognostic factors. Although random-
isation will make it unlikely that serious long-term imbalance
between treatments groups will occur in respect of prognostic
factors, these might occur in early interim analyses, especially if
randomisation is not stratiﬁed. It is therefore sensible to adjust for
important prognostic factors at interim analyses. The simulated
procedures we present in this paper are stratiﬁed for the number
and grade of tumours removed at resection and for the maximum
diameter of the largest tumour.3.2. Anticipated ﬂow of information and expected termination
of the trial
Table 1 shows how patient numbers and information are likely
to increase over time if a recruitment rate of 170 patients per year
for 33 months is maintained. Exponential forms for the survival
curves are used in the absence of any more speciﬁc prior
information.
The stopping boundaries of the test are shown in Fig. 1c, and its
properties in Table 2. The trial recruited to the two treatment arms
at equal rates. We can observe that when the real treatment
difference here is as speciﬁed (HR¼ 0.535), the expected number of
recurrences at termination is 65. When the anticipated improve-
ment is only HR¼ 0.731, the expected number of recurrences is 80.
These numbers are well below 108, the number of recurrences
required by the conventional design. Even the 90th percentile of
the numbers of recurrences for a modest improvement such as
HR¼ 0.731 is not far above 108.
If recruitment were to continue until the time of analysis, then it
would take 32 months for 108 recurrences required by the ﬁxed-
sample size design to accrue. The MRC Urological Cancer Working
Table 1
Anticipated ﬂow of information for the sequential design.
Calendar months
since start of study
Number
of
patients
Number of
recurrences
Information
(V)
6 85 3 0.76
9 127 9 2.22
12 170 17 4.33
15 212 28 7.03
18 255 39 9.73
21 297 50 12.43
24 340 61 15.13
30 425 98 24.41
36 469 135 33.68
42 469 164 40.75
48 469 182 45.22
60 469 205 51.04
Table 2
Properties at termination of the sequential design.
Hazard
ratio
(HR)
Probability
of crossing
upper
boundary
Probability
of crossing
lower
boundary
Expected
number of
recurrences
(calendar months
since start study)
90th Percentile
of recurrences
(calendar months
since start
of study)
1.87 0.0000026 0.900 65 (21) 104 (28)
1.37 0.00034 0.362 80 (24) 116 (30)
1.0 0.025 0.025 72 (23) 98 (27)
0.73 0.362 0.00034 80 (24) 116 (30)
0.54 0.900 0.0000026 65 (21) 104 (28)
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recruited and followed these patients up. A principal analysis was
performed after a further 24 months by which time 148 recur-
rences had accumulated. Stopping was in accordance with the non-
sequential design actually adopted for the trial.
In order to have sufﬁcient patients and follow-up data to
contemplate early stopping, and to justify asymptotic model
assumptions, the ﬁrst interim analysis is done on the data available
in June 1985, 15 months after entry of the ﬁrst patient and at three
monthly intervals thereafter for a further year. The aimwas to have
annual interim looks after this regular schedule, with an extra look
within the ﬁrst one year period. Interim analyses were thus
schedule at the following dates: 1st at 15 months in June 1985, 2nd
at 18 months in September 1985, 3rd at 21 months in December
1985, 4th at 24 months in March 1986, 5th at 27 months in June
1986, 6th at 36 months in March 1987, 7th at 48 months in March
1988, 8th at 60 months in February 1989 and 9th at 72 months in
February 1990.3.3. Results from the sequential analysis
According to the above plan, the ﬁrst interim look was per-
formed 15 months after the ﬁrst recruitment. Patients with no
recurrence at the time of analysis were considered censored at that
time. A Cox’s regression model was applied to the available data in
order to investigate the relationship between recurrence time and
possible prognostic factors. The most important variable in pre-
dicting recurrence time was the maximum diameter of the largest
tumour, ﬁtted with two levels: 0–1 cm and 1 cm (p¼ 0.03). Grade
of tumour assessed by the reference pathologist, ﬁtted with three
levels: 1–2, 3–4 and 5,(p¼ 0.18); and number of tumours, ﬁttedFig. 1. Sample path of the sequential reanalysis of the MRC-BS03 trial.with two levels: 0–2 and 2,(p¼ 0.20), were also found to be of
some prognostic importance. These factors had also proved to be
important prognostic factors in a previous study.9 Consequently,
the ﬁrst and all subsequent interim analyses were stratiﬁed for
these prognostic factors, forming twelve strata in all. Stratiﬁcation
had the advantage over covariate adjustment in a Cox model of not
assuming proportional hazards between strata.
In this reanalysis, the sequential version of the trial was stopped
at the ﬁfth interim analysis, 27 months after recruitment of the ﬁrst
patient, with 305 patients recruited and 121 recurrences accumu-
lated. Final test statistics were V¼ 28.6 and Z¼ 13.4. The null
hypothesis was rejected, suggesting that there is a signiﬁcant
advantage of MMCx1 on the recurrence rate of bladder cancer. The
p-value at the time of stopping, allowing for interim looks, was
p¼ 0.04. The 95% conﬁdence interval for the hazard ratio was (0.44,
0.98), with an estimated hazard ratio of 0.657. All values were
adjusted for previous interim looks.
After the trial was stopped and recruitment terminated, data
would continue to accumulate from patients who had already been
treated. A further 27 recurrences were accumulated after a follow
up to 72 months. In practice, to achieve maximum beneﬁt from the
sequential design, the analysis conducted at the time of stopping
would be considered deﬁnitive, and would be submitted for
publication. However, it is of interest, both in this exercise and in
real life, to continue follow-up and to investigate whether the trial
conclusion are maintained. Appropriate analyses to incorporate the
extra data were performed following Whitehead.17 The same
conclusion was reached: rejection of the null hypothesis in favour
of superiority of one instillation of mitomycin-c. The values of the
test statistics were V¼ 36.69 and Z¼ 15.87. The p-value was
P¼ 0.04 and the 95% conﬁdence interval for the hazard ratio was
(0.46, 0.98), with an estimate of HR¼ 0.67. The full sample path,
including overrunning due to the follow up of patients already
recruited is shown in Fig. 1. also shows an inner pair of crooked
boundaries, known as Christmas tree boundaries. These provide
a correction for the discrete and irregular nature of monitoring.16,2
It is sufﬁcient for the sample path to reach these inner boundaries
for stopping to occur.
3.4. Comparison with the actual trial
Table 3 shows a summary of the recurrences classiﬁed according
to treatment group and the time elapsed between randomisation of
the patient and recurrence.
The comparative analyses presented in Table 4 show that the
conclusion of the trial at the time of stopping, and after follow up is
incorporated, were both consistent with a ﬁnal ﬁxed-sample
analysis at 72 months. In the sequential re-analysis recruitment
was stopped 27 months from entry of the ﬁrst patient, and an
analysis with the intended power was available. This effectively
reduced the duration of the trial by 45 months and the number of
recurrences accumulated at the time of analysis by 27. Since we
were re-analysing a ﬁxed-sample trial, the whole of the
Table 3
Summary of recurrences by time since randomisation and by treatment group.
Time interval since
randomisation (days)
mitomycin-c group Control group
Number of recurrences
during interval
Number at risk at
start of interval
Number of recurrences
during interval
Number at risk at
start of interval
(0, 360) 41 148 68 157
(360, 450) 3 107 4 89
(450, 540) 0 104 4 85
(540, 720) 7 104 5 81
¼> 720 9 97 7 76
Table 4
Comparison of analyses.
Hazard
ratio (HR)
95% C.I. for HR P-value Calendar months
since start of study
Number of
events
Number of
patients
Sequential 0.657 (0.44, 0.98) 0.042 27 121 305
Overrunning 0.67 (0.46, 0.98) 0.040 72 148 305
Fixed sample 0.571 (0.41, 0.80) 0.001 72 148 305
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behaved, had the trial been left to continue. This of course is an
impossible exercise for a real sequential trial! In case the sample
path continued to increase, showing that any further analysis,
including the actual ﬁxed-sample analysis, would have been in
agreement with the sequential analysis performed.
The Kaplan–Meier survival curves presented in Fig. 2 suggest
that it is the non-proportionality of hazards which caused the ﬁrst
MRC analysis to showed a non-signiﬁcant conclusion. The curves
are indistinguishable for the ﬁrst 100 days, and then they separate.
Such behaviour is inconsistent with the proportional hazards
assumption. For this reason the stratiﬁed analysis brings the
conclusion closer to that of the deﬁnite MRC ﬁxed-sample study.
The stratiﬁed analysis is more appropriate and powerful when
hazards are indeed non-proportional.4. Discussion
In this paper, and in Refs.,4,5 we have shown how sequential
methodologymight be applied to clinical trials collecting long-term
survival data. The advantages of themethodology are strong. It is no
longer ethically acceptable to collect long-term follow-up data
without periodic assessments of the accumulating results, prefer-
ably by an independent Data and Safety Monitoring Committee.Fig. 2. Survival curves for the MMCx1 and Control groups.Such assessment could lead to design modiﬁcations or to termi-
nation of the study, and as long as frequentist analyses are to be
presented, allowance for the interim looks at the data should be
made. This necessitates the use of designs which permit such
adjustment to be made, and the designs should also be chosen to
ensure that resources are not devoted to trials which have evidently
become futile. Statistical methodology and computer software are
now available for the implementation of this approach. As
conventional calculations of ﬁxed-sample size or ﬁxed study
durations are often based on guesses concerning survival and
recruitment patterns, they should not be viewed as a gold standard
or as an automatic default design.
In practice a Data and Safety Monitoring Committee may decide
to override a formal stopping rule, continuing despite a boundary
being crossed or stopping despite no boundary being reached. Such
decisions need to be taken with care and documented in detail:
when designs are discussed with the Committee in advance this
situation should be unusual. Our retrospective simulation cannot
incorporate this sort of Data and Safety Monitoring Committee’s
prerogative, and so adheres to the formal rules.
The difﬁculties inherent in the sequential approach should not,
however, be overlooked. The conclusions of any survival study are
dependent on the nature of the assumptions and models used in
the analysis. Particularly important for survival data is the
assumption of proportional hazard inherent in using a Cox
regression model for analysis. Although this is the case in a ﬁxed-
sample design, unfortunately, the inﬂuence of such assumption
may be most important at early interim analyses of a sequential
trial, precisely when there is the least data available to test them. In
such circumstances, the analysis and interpretations of the results
should be done cautiously. There is always the possibility that
a longer follow-up might reveal a difference balance of treatment
advantage. A sequential design may face the investigator with
a clear choice: stop now because of the apparent message of the
data, or press on to conﬁrm the model on which that message is
based. Scientiﬁcally, without regard for ethics, urgency or cost, one
would press on in order to amass irrefutable evidence. In the
context of clinical trial this may not be an acceptable action.
In order to reduce the potential of interim analyses to mislead,
there are several tools which can be employed. Some have been
illustrated here: delay the ﬁrst look at the data so that its conclu-
sions have some credibility; adjust for prognostic factors which
might affect outcome; and choose a survival model which is
resistant to anticipated departures from assumptions. These
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that they should be reassessed at interim analyses, and design
changes made if necessary. The importance of getting the model
right seems to override concerns about inﬂation of error rates due
to such secondary interim analyses.
Concern over stopping inappropriately at early interim analyses,
could be addressed by setting more stringent stopping criteria at
these looks. The O’Brien and Fleming10 design achieves this auto-
matically. However, early stopping can be desirable if appropriate,
and here we have attempted to reﬁne the interim analysis rather
than introducing unwanted conservatism.
Alternative approaches to the conduct of sequential trials have
been suggested by Bayesian statisticians.13 It is interesting that
Bayesian methods also call for careful assessment of prior infor-
mation in order to construct the design of the trial. These methods
too are strongly model dependent, and an assessment of model
assumptions and the inﬂuence of prognostic factors would be
equally important to the Bayesian approach. Such design lead to
a valid Bayesian analysis, but pay no direct attention to achieving
set levels of error probability.
In this example we have concentrated on only two arms of the
trial with three treatment arms and have not considered the
possibility of stopping recruitment to one armwhile continuing the
recruitment into the other two. The complexity of the decision-
making in such three arm trials emphasises the need for careful
prior planning. A ﬁnal consideration is that the interim analyses
conducted in this paper are idealised, in that all of the events which
had occurred by the date of the interim are included. In practice,
there would be a delay in data reporting. We have no way of
recovering the true state of the database at these dates, and so this
practical issue cannot be explored. It is to be hoped that the
intention to conduct interim analyses would anyway have a bene-
ﬁcial effect on completeness of the database. As this is a reanalysis
of a completed study, some of the design choices suggested in the
following section beneﬁt from hindsight. However, this does not
invalidate the exercise, which demonstrates the importance of
questioning the assumptions of the model at the design stage,
when interim analyses are to be performed.
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